CompletedNCT00664703
Lobeline, methylphenidate or placebo for adult ADHD
About this title
Read the official source — NCT00664703Medication studyAges 21–45United States
Understand this study
Who was this study for?
Listed age limits: 21 years to 45 years.
What did participation involve?
The protocol includes: Completing questionnaires.
- Listed locations
- LexingtonSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateJuly 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 13
- Sponsor
- Yaupon Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 21 Years to 45 Years
- Official registry ID
- NCT00664703
- Official title
Show the full official title
A Double-Blind, Double-Dummy, Placebo-Controlled, Dose Ranging Study of 7.5, 15, and 30 mg of Sublingual Lobeline in Adult ADHD Patients
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Lexington
Interested in joining this study?
Questions about this study
What did participation involve?
The protocol called for participants to complete questionnaires.
Who is behind this study?
The study sponsor is Yaupon Therapeutics.
Did this study involve medication?
Yes. The study involved medication, including Lobeline sulfate, Methylphenidate HCl and Placebo.
Who was this study for?
Listed age limits: 21 years to 45 years.
